Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Incidence and clearance of anal HPV-16 and HPV-18 infection, and their determinants, among HIV-infected men who have sex with men in France.

Alberts CJ, Heard I, Canestri A, Marchand L, Fléjou JF, Piroth L, Ferry T, Didelot JM, Siproudhis L, Henno S, Poizot-Martin I, Darragh TM, Clifford GM, Combes JD, Etienney I; ANRS EP57 APACHES Study group.

J Infect Dis. 2019 Nov 22. pii: jiz623. doi: 10.1093/infdis/jiz623. [Epub ahead of print]

PMID:
31754686
2.

Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction.

Combes JD, Clifford GM, Günthard HF, Hauser C, Darling KEA, Valladares P, Battegay M, Waldeck F, Bernasconi E, Bertisch B, Hirsch HH, Brenner N, Waterboer T, Scherrer AU; Swiss HIV Cohort Study.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784. [Epub ahead of print]

PMID:
31722114
3.

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.

Vink FJ, Meijer CJLM, Clifford GM, Poljak M, Oštrbenk A, Petry KU, Rothe B, Bonde J, Pedersen H, de Sanjosé S, Torres M, Del Pino M, Quint WGV, Cuschieri K, Boada EA, van Trommel NE, Lissenberg-Witte BI, Floore AN, Hesselink AT, Steenbergen RDM, Bleeker MCG, Heideman DAM.

Int J Cancer. 2019 Aug 7. doi: 10.1002/ijc.32614. [Epub ahead of print]

PMID:
31390052
4.

Cervical cancer risk in women living with HIV across four continents: A multicohort study.

Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, Taghavi K, Moore RD, Goedert JJ, Gill MJ, Silverberg MJ, D'Souza G, Patel P, Castilho JL, Ross J, Sohn A, Bani-Sadr F, Taylor N, Paparizos V, Bonnet F, Verbon A, Vehreschild JJ, Post FA, Sabin C, Mocroft A, Dronda F, Obel N, Grabar S, Spagnuolo V, Quiros-Roldan E, Mussini C, Miro JM, Meyer L, Hasse B, Konopnicki D, Roca B, Barger D, Clifford GM, Franceschi S, Egger M, Bohlius J.

Int J Cancer. 2019 Jun 19. doi: 10.1002/ijc.32260. [Epub ahead of print]

PMID:
31215037
5.

Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.

Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, Wu T, Hessol NA, Shvetsov Y, Ortiz AP, Grinsztejn B, Moscicki AB, Heard I, Del Refugio González Losa M, Kojic EM, Schim van der Loeff MF, Wei F, Longatto-Filho A, Mbulawa ZA, Palefsky JM, Sohn AH, Hernandez BY, Robison K, Simpson S Jr, Conley LJ, de Pokomandy A, van der Sande MAB, Dube Mandishora RS, Volpini LPB, Pierangeli A, Romero B, Wilkin T, Franceschi S, Hidalgo-Tenorio C, Ramautarsing RA, Park IU, Tso FK, Godbole S, D'Hauwers KWM, Sehnal B, Menezes LJ, Heráclio SA, Clifford GM.

Lancet Infect Dis. 2019 Aug;19(8):880-891. doi: 10.1016/S1473-3099(19)30164-1. Epub 2019 Jun 13.

6.

Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status.

Mpunga T, Chantal Umulisa M, Tenet V, Rugwizangoga B, Milner DA Jr, Munyanshongore C, Heideman DAM, Bleeker MCG, Tommasino M, Franceschi S, Baussano I, Gheit T, Sayinzoga F, Clifford GM.

Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32491. [Epub ahead of print]

PMID:
31173641
7.

Hopes for Prevention of Anal Cancer in Women.

Clifford GM, Combes JD.

J Infect Dis. 2019 Apr 23. pii: jiz191. doi: 10.1093/infdis/jiz191. [Epub ahead of print] No abstract available.

PMID:
31100126
8.

Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women.

Clifford GM, Tenet V, Georges D, Alemany L, Pavón MA, Chen Z, Yeager M, Cullen M, Boland JF, Bass S, Steinberg M, Raine-Bennett T, Lorey T, Wentzensen N, Walker J, Zuna R, Schiffman M, Mirabello L.

Papillomavirus Res. 2019 Jun;7:67-74. doi: 10.1016/j.pvr.2019.02.001. Epub 2019 Feb 6.

9.
10.

Prevalence and risk factors of human polyomavirus infections in non-malignant tonsils and gargles: the SPLIT study.

Kourieh A, Combes JD, Tommasino M, Dalstein V, Clifford GM, Lacau St Guily J, Clavel C, Franceschi S, Gheit T, For The Split Study Group.

J Gen Virol. 2018 Dec;99(12):1686-1698. doi: 10.1099/jgv.0.001156. Epub 2018 Nov 8.

PMID:
30407150
11.

Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans.

Chen Z, DeSalle R, Schiffman M, Herrero R, Wood CE, Ruiz JC, Clifford GM, Chan PKS, Burk RD.

PLoS Pathog. 2018 Nov 1;14(11):e1007352. doi: 10.1371/journal.ppat.1007352. eCollection 2018 Nov.

12.

Prevalence of human herpesviruses infections in nonmalignant tonsils: The SPLIT study.

Kourieh A, Gheit T, Tommasino M, Dalstein V, Clifford GM, Lacau St Guily J, Clavel C, Franceschi S, Combes JD; SPLIT study group.

J Med Virol. 2019 Apr;91(4):687-697. doi: 10.1002/jmv.25338. Epub 2018 Nov 13.

PMID:
30318627
13.
14.

Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.

Clifford GM, Siproudhis L, Piroth L, Poizot-Martin I, Radenne S, Reynes J, Lesage A, Heard I, Henno S, Fléjou JF, Marchand L, Combes JD, Etienney I; ANRS EP57 APACHES Study group.

AIDS. 2018 Oct 23;32(16):2363-2371. doi: 10.1097/QAD.0000000000001947.

PMID:
30005009
15.

Human papillomavirus detection in gargles, tonsil brushings, and frozen tissues in cancer-free patients.

Combes JD, Clavel C, Dalstein V, Gheit T, Clifford GM, Tommasino M, Franceschi S, Lacau St Guily J; SPLIT study group.

Oral Oncol. 2018 Jul;82:34-36. doi: 10.1016/j.oraloncology.2018.05.001. Epub 2018 May 11. No abstract available.

PMID:
29909899
16.

Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda.

Umulisa MC, Franceschi S, Baussano I, Tenet V, Uwimbabazi M, Rugwizangoga B, Heideman DAM, Uyterlinde AM, Darragh TM, Snijders PJF, Sayinzoga F, Clifford GM.

BMC Womens Health. 2018 Apr 24;18(1):59. doi: 10.1186/s12905-018-0549-5.

17.

A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda.

Mpunga T, Znaor A, Uwizeye FR, Uwase A, Munyanshongore C, Franceschi S, Clifford GM.

Int J Cancer. 2018 Sep 15;143(6):1348-1355. doi: 10.1002/ijc.31537. Epub 2018 Apr 26.

18.

Options for design of real-world impact studies of single-dose vaccine schedules.

Franceschi S, Clifford GM, Baussano I.

Vaccine. 2018 Aug 6;36(32 Pt A):4816-4822. doi: 10.1016/j.vaccine.2018.02.002. Epub 2018 Mar 21.

19.

Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men.

Combes JD, Heard I, Poizot-Martin I, Canestri A, Lion A, Piroth L, Didelot JM, Ferry T, Patey O, Marchand L, Flejou JF, Clifford GM, Etienney I; ANRS EP57 APACHES Study group.

J Infect Dis. 2018 Apr 23;217(10):1535-1543. doi: 10.1093/infdis/jiy059. Erratum in: J Infect Dis. 2018 Sep 8;218(8):1350.

PMID:
29394362
20.

Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.

Lin C, Franceschi S, Clifford GM.

Lancet Infect Dis. 2018 Feb;18(2):198-206. doi: 10.1016/S1473-3099(17)30653-9. Epub 2017 Nov 17.

21.

Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan.

Tshomo U, Franceschi S, Tshokey T, Tobgay T, Baussano I, Tenet V, Heideman DAM, Snijders PJF, Clifford GM.

Oncotarget. 2017 Aug 2;8(42):72438-72446. doi: 10.18632/oncotarget.19783. eCollection 2017 Sep 22.

22.

HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis.

Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B, Cullen M, Boland JF, Wentzensen N, Nelson CW, Raine-Bennett T, Chen Z, Bass S, Song L, Yang Q, Steinberg M, Burdett L, Dean M, Roberson D, Mitchell J, Lorey T, Franceschi S, Castle PE, Walker J, Zuna R, Kreimer AR, Beachler DC, Hildesheim A, Gonzalez P, Porras C, Burk RD, Schiffman M.

Cell. 2017 Sep 7;170(6):1164-1174.e6. doi: 10.1016/j.cell.2017.08.001.

23.

Cervical cancer screening in rural Bhutan with the careHPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan).

Baussano I, Tshering S, Choden T, Lazzarato F, Tenet V, Plummer M, Franceschi S, Clifford GM, Tshomo U.

BMJ Open. 2017 Jul 19;7(7):e016309. doi: 10.1136/bmjopen-2017-016309.

24.

Seroprevalence of antibodies against Kaposi's sarcoma-associated herpesvirus among HIV-negative people in China.

Zhang T, Liu Z, Wang J, Minhas V, Wood C, Clifford GM, He N, Franceschi S.

Infect Agent Cancer. 2017 May 30;12:32. doi: 10.1186/s13027-017-0142-9. eCollection 2017.

25.

Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan.

Tshomo U, Franceschi S, Tshokey T, Tobgay T, Baussano I, Tenet V, Snijders PJ, Gheit T, Tommasino M, Vorsters A, Clifford GM.

Virol J. 2017 Apr 8;14(1):74. doi: 10.1186/s12985-017-0744-2.

26.

Cervical screening: toward an equal risk/equal management approach, irrespective of HIV status.

Franceschi S, Clifford GM.

AIDS. 2017 Apr 24;31(7):1045-1046. doi: 10.1097/QAD.0000000000001453. No abstract available.

PMID:
28350579
27.

CD4/CD8 ratio and lung cancer risk.

Clifford GM, Lise M, Franceschi S, Scherrer AU.

Lancet HIV. 2017 Mar;4(3):e103. doi: 10.1016/S2352-3018(17)30027-9. No abstract available.

PMID:
28254148
28.

Prevalence of human papillomavirus in tonsil brushings and gargles in cancer-free patients: The SPLIT study.

Combes JD, Dalstein V, Gheit T, Clifford GM, Tommasino M, Clavel C, Lacau St Guily J, Franceschi S; SPLIT study group.

Oral Oncol. 2017 Mar;66:52-57. doi: 10.1016/j.oraloncology.2017.01.001. Epub 2017 Jan 18.

PMID:
28249648
29.

Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer.

Clifford GM, Tully S, Franceschi S.

Clin Infect Dis. 2017 May 1;64(9):1228-1235. doi: 10.1093/cid/cix135. Review.

30.

Hepatitis C virus seroprevalence in the general female population of 9 countries in Europe, Asia and Africa.

Clifford GM, Waterboer T, Dondog B, Qiao YL, Kordzaia D, Hammouda D, Keita N, Khodakarami N, Raza SA, Sherpa AT, Zatonski W, Pawlita M, Plummer M, Franceschi S.

Infect Agent Cancer. 2017 Feb 2;12:9. doi: 10.1186/s13027-017-0121-1. eCollection 2017.

31.

Human papillomavirus antibody response following HAART initiation among MSM.

Combes JD, Clifford GM, Egger M, Cavassini M, Hirsch HH, Hauser C, Calmy A, Schmid P, Bernasconi E, Günthard HF, Franceschi S, Waterboer T, Scherrer AU; Swiss HIV Cohort Study.

AIDS. 2017 Feb 20;31(4):561-569. doi: 10.1097/QAD.0000000000001354.

32.

Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa.

Clifford GM, de Vuyst H, Tenet V, Plummer M, Tully S, Franceschi S.

J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):332-339.

33.

Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.

Clifford GM, Vaccarella S, Franceschi S, Tenet V, Umulisa MC, Tshomo U, Dondog B, Vorsters A, Tommasino M, Heideman DA, Snijders PJ, Gheit T.

J Clin Microbiol. 2016 Aug;54(8):2031-8. doi: 10.1128/JCM.00618-16. Epub 2016 May 25.

34.

Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme.

Ngabo F, Franceschi S, Baussano I, Umulisa MC, Snijders PJ, Uyterlinde AM, Lazzarato F, Tenet V, Gatera M, Binagwaho A, Clifford GM.

BMC Infect Dis. 2016 May 24;16:225. doi: 10.1186/s12879-016-1539-6.

35.

Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.

Franceschi S, Chantal Umulisa M, Tshomo U, Gheit T, Baussano I, Tenet V, Tshokey T, Gatera M, Ngabo F, Van Damme P, Snijders PJ, Tommasino M, Vorsters A, Clifford GM.

Int J Cancer. 2016 Aug 1;139(3):518-26. doi: 10.1002/ijc.30092. Epub 2016 Apr 15.

36.

Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population.

Hang D, Yin Y, Han J, Jiang J, Ma H, Xie S, Feng X, Zhang K, Hu Z, Shen H, Clifford GM, Dai M, Li N.

Virology. 2016 Jan 15;488:156-61. doi: 10.1016/j.virol.2015.11.016. Epub 2015 Nov 30.

37.

Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV cohort study.

Clifford GM, Franceschi S, Keiser O, Schöni-Affolter F, Lise M, Dehler S, Levi F, Mousavi M, Bouchardy C, Wolfensberger A, Darling KE, Staehelin C, Bertisch B, Kuenzli E, Bernasconi E, Pawlita M, Egger M; Swiss HIV Cohort Study.

Int J Cancer. 2016 Apr 1;138(7):1732-40. doi: 10.1002/ijc.29913. Epub 2015 Nov 20.

38.

Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide.

Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM; IARC HPV Variant Study Group.

J Virol. 2015 Oct;89(20):10680-7. doi: 10.1128/JVI.01747-15. Epub 2015 Aug 12.

39.

Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance.

Baussano I, Tshomo U, Clifford GM, Tenet V, Tshokey T, Franceschi S.

BMC Womens Health. 2014 Nov 30;14:147. doi: 10.1186/s12905-014-0147-0.

40.

Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China).

Serrano B, Alemany L, Ruiz PA, Tous S, Lima MA, Bruni L, Jain A, Clifford GM, Qiao YL, Weiss T, Bosch FX, de Sanjosé S.

Cancer Epidemiol. 2014 Dec;38(6):748-56. doi: 10.1016/j.canep.2014.09.003. Epub 2014 Oct 8.

41.

Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme.

Tshomo U, Franceschi S, Dorji D, Baussano I, Tenet V, Snijders PJ, Meijer CJ, Bleeker MC, Gheit T, Tommasino M, Clifford GM.

BMC Infect Dis. 2014 Jul 22;14:408. doi: 10.1186/1471-2334-14-408.

42.

Judging the carcinogenicity of rare human papillomavirus types.

Combes JD, Guan P, Franceschi S, Clifford GM.

Int J Cancer. 2015 Feb 1;136(3):740-2. doi: 10.1002/ijc.29019. Epub 2014 Jun 19. No abstract available.

43.

Prevalence of HPV infection and other risk factors in a Fijian population.

Foliaki S, Brewer N, Pearce N, Snijders PJ, Meijer CJ, Waqatakirewa L, Clifford GM, Franceschi S.

Infect Agent Cancer. 2014 Apr 28;9:14. doi: 10.1186/1750-9378-9-14. eCollection 2014.

44.

Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.

Chen AA, Heideman DA, Boon D, Gheit T, Snijders PJ, Tommasino M, Franceschi S, Clifford GM; IARC HPV Variant Study Group.

J Virol. 2014 Apr;88(8):4514-21. doi: 10.1128/JVI.03534-13. Epub 2014 Feb 5.

45.

Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.

Chen AA, Heideman DA, Boon D, Chen Z, Burk RD, De Vuyst H, Gheit T, Snijders PJ, Tommasino M, Franceschi S, Clifford GM.

Virology. 2014 Jan 5;448:356-62. doi: 10.1016/j.virol.2013.10.033. Epub 2013 Nov 12.

47.

Human papillomavirus type 16 E6 variants in France and risk of viral persistence.

Cornet I, Gheit T, Clifford GM, Combes JD, Dalstein V, Franceschi S, Tommasino M, Clavel C.

Infect Agent Cancer. 2013 Jan 23;8(1):4. doi: 10.1186/1750-9378-8-4.

48.

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease.

Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjosé S.

Infect Agent Cancer. 2012 Dec 29;7(1):38. doi: 10.1186/1750-9378-7-38.

49.

HPV16 genetic variation and the development of cervical cancer worldwide.

Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, Franceschi S, Tommasino M, Clifford GM.

Br J Cancer. 2013 Jan 15;108(1):240-4. doi: 10.1038/bjc.2012.508. Epub 2012 Nov 20.

50.

Human papillomavirus types in glandular lesions of the cervix: a meta-analysis of published studies.

Guan P, Clifford GM, Franceschi S.

Int J Cancer. 2013 Jan 1;132(1):248-50. doi: 10.1002/ijc.27663. Epub 2012 Jun 28. No abstract available.

Supplemental Content

Loading ...
Support Center